|
Age at screening (years)
|
No. of women screened in the age group
|
No. of HPV-positive (% of women screened) (95% CI)
|
Colposcopy attendance among HPV-positive
|
Histopathology resultsa (% of women attending colposcopyb) (95% CI)
|
Yield of the screening effortb (% of total women screened)
|
|---|
|
CIN2+
|
CIN3+
|
CIN2+
|
CIN3+
|
|---|
|
30–34
|
77
|
35 (45.5%) (34.1–57.2%)
|
27 (77.1%)
|
1 (3.8%) (0.1–19.6%)
|
1 (3.8%) (0.1–19.6%)
|
1.3%
|
1.3%
|
|
35–39
|
160
|
57 (35.6%) (28.2–43.6%)
|
41 (71.9%)
|
2 (5.0%) (0.6–16.9%)
|
2 (5.0%) (0.6–16.9%)
|
1.3%
|
1.3%
|
|
40–44
|
134
|
46 (34.3%) (26.3–43.0%)
|
40 (87.0%)
|
4 (10.0%) (2.8–23.7%)
|
3 (7.5%) (1.6–20.4%)
|
3.0%
|
2.2%
|
|
45–49
|
71
|
41 (57.7%) (45.4–69.4%)
|
35 (85.4%)
|
4 (11.4%) (3.2–26.7%)
|
3 (8.6%) (1.8–23.1%)
|
5.6%
|
4.2%
|
|
Total
|
442
|
179 (40.5%) (35.9–45.2%)
|
143 (79.9%)
|
11 (7.8%) (4.0–13.5%)
|
9 (6.4%) (3.0–11.8%)
|
2.5%
|
2.0%
|
- aCIN2+ and CIN3+ includes one case of squamous cell carcinoma in a 49-year old woman
- bHistopathology report was not completed for two participants due to COVID-19 pandemic spread. These two participants were excluded from the denominator
